Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease

NCT ID: NCT00603590

Last Updated: 2009-10-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 475 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2008-07-31

Brief Summary

Cardiovascular is a major cause of mortality in Iran, accounting for 45.7% of deaths. In Golestan (North Eastern Iran) preliminary findings from follow-up of the Golestan Cohort are consistent with national figures: with 45% (at least 22 of 48 deaths) of all deaths attributed to cardiovascular events. Cardiovascular diseases will become an increasing problem as the Iranian population ages.

In 2003 Law and Wald proposed prevention of cardiovascular disease using fixed-dose combination therapy combining antihypertensive, lipid lowering and antiplatelet drugs in a single preparation. They proposed that this treatment should be offered to all persons at high risk of cardiovascular disease whether or not they have elevated blood pressure or elevated serum lipid concentrations.

This pilot study aims to investigate the safety and efficacy of fixed-dose combination therapy with two antihypertensive drugs, aspirin and atorvastatin in a population who would not currently be considered eligible for antihypertensive treatment or for lipid lowering treatment.

Methods:

This is a double-blind randomized controlled trial. The intervention group will be assigned to take a tablet consisting of a single daily tablet comprising Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg. The control group will be assigned to an identical placebo.

The population studied includes men aged 50 to 80 (inclusive) and women aged 55 to 80 (inclusive) who are currently not eligible for or taking antihypertensive or lipid lowering therapy. Persons who are found at baseline to have blood pressure >160/100 mm Hg, total cholesterol >240mg/dL, existing cardiovascular disease or to be taking antihypertensive ore lipid lowering therapy are excluded.

It is intended to randomize and follow up 500 subjects for 12 months. The primary outcome for the purpose of sample size calculation is change in systolic blood pressure. Additional outcomes include change in diastolic blood pressure, change in LDL cholesterol and occurrence of adverse events.

Conditions

Cardiovascular Disease; Hypertension; Hyperlipidemia; Heart Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Polypill

Fixed dose combination therapy with Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg

Group Type: EXPERIMENTAL

Polypill

Intervention Type: DRUG

Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily

Control

Identical placebo

Group Type: PLACEBO_COMPARATOR

Placebo drug

Intervention Type: DRUG

Inactive tablet Once a day Identical in appearance to intervention drug

Interventions

Polypill

Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily

Intervention Type: DRUG

Placebo drug

Inactive tablet Once a day Identical in appearance to intervention drug

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

All men over 50 to 80 and all women 55 to 80 who are resident in Kalaleh, Golestan, for at least one year.

Exclusion Criteria

• Existing cardiovascular disease (stroke, transient ischaemic attack, myocardial infarction or angina)
• Already taking antihypertensive drugs, aspirin or statins
• Already have clinical indications for treatment with antihypertensive drugs, aspirin or statins.

• Blood pressure >160/100 mm Hg
• Total Cholesterol > 240 mg/dL (or LDL >190 mg/dL)
• Probable diabetes: HbA1c >6.0

Contraindication to a component of the Polypill

Contraindications to aspirin

• Previous history of allergy to aspirin
• History of peptic ulcer bleeding in whole life or endoscopic evidence of peptic ulcer within the past 3 months

Contraindications to statins

• Liver failure Contraindications to further blood pressure lowering
• Systolic blood pressure ≤90 mm Hg or diastolic blood pressure ≤70 mm Hg
• Symptomatic postural hypotension
• Difference between mean seated BP and standing BP greater than 20 mm Hg

Contraindications to thiazide

• Uric acid >8 for men and uric acid >6 for women / gout (~10%)
• Creatinine >1.2 mg/dl

Other predominant medical problem that may limit compliance with study treatment including:

• History of alcohol abuse: more than 60cc for women and more than 80cc for men
• History of drug abuse: IV drug abuser or eating or smoking more than 4 times a week
• Limiting psychiatric illness (eg: mania, schizophrenia, severe depression, psychosis or dementia)
• Limiting physical disability sufficient to prevent subject from walking
• Other life-threatening condition such as cancer

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Birmingham

OTHER

Sponsor Role: collaborator

Tehran University of Medical Sciences

OTHER

Sponsor Role: lead

Responsible Party

Tehran University of Medical Sciences

Principal Investigators

Reza Malekzadeh, M.D.

Role: STUDY_CHAIR

Tehran University of Medical Sciences

Fatemeh Malekzadeh, M.D.

Role: PRINCIPAL_INVESTIGATOR

Tehran University of Medical Sciences

Mansoor Rastegarpanah, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Tehran University of Medical Sciences

Kar K Cheng, PhD

Role: STUDY_CHAIR

University of Birmingham

Tom P Marshall, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Birmingham

Akram Pourshams, PhD

Role: STUDY_DIRECTOR

Tehran University of Medical Sciences

Locations

Kalaleh Heart Study Center

Kalāleh, Golestan Province, Iran

Countries

Iran

References

Rastegarpanah M, Malekzadeh F, Thomas GN, Mohagheghi A, Cheng KK, Marshall T. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"? Arch Iran Med. 2008 May;11(3):306-13. No abstract available.

Reference Type: BACKGROUND

PMID: 18426322 (View on PubMed)

Other Identifiers

CCT-NAPN 15388

Identifier Type: -

Identifier Source: secondary_id

301/148

Identifier Type: -

Identifier Source: org_study_id